MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 10, 2007; DOI: 10.1124/mol.107.037333


0026-895X/07/7204-907-920$20.00
Mol Pharmacol 72:907-920, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.037333v1
72/4/907    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erreger, K.
Right arrow Articles by Traynelis, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erreger, K.
Right arrow Articles by Traynelis, S. F.

Subunit-Specific Agonist Activity at NR2A-, NR2B-, NR2C-, and NR2D-Containing N-Methyl-D-aspartate Glutamate Receptors

Kevin Erreger, Matthew T. Geballe, Anders Kristensen, Philip E. Chen, Kasper B. Hansen, C. Justin Lee, Hongjie Yuan, Phuong Le, Polina N. Lyuboslavsky, Nicola Micale, Lars Jørgensen, Rasmus P. Clausen, David J. A. Wyllie, James P. Snyder, and Stephen F. Traynelis

Department of Pharmacology, Emory University School of Medicine, Rollins Research Center, Atlanta, Georgia (K.E., A.K., K.B.H., C.J.L., H.Y., P.L., P.N.L., S.F.T.); Department of Chemistry, Emory University, Atlanta, Georgia (M.T.G., J.P.S.); Centre for Neuroscience Research, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, United Kingdom (P.E.C., D.J.A.W.); and Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark (N.M., L.J., R.P.C.).

The four N-methyl-D-aspartate (NMDA) receptor NR2 subunits (NR2A-D) have different developmental, anatomical, and functional profiles that allow them to serve different roles in normal and neuropathological situations. Identification of subunit-selective NMDA receptor agonists, antagonists, or modulators could prove to be both valuable pharmacological tools as well as potential new therapeutic agents. We evaluated the potency and efficacy of a wide range of glutamate-like compounds at NR1/NR2A, NR1/NR2B, NR1/NR2C, and NR1/NR2D receptors. Twenty-five of 53 compounds examined exhibited agonist activity at the glutamate binding site of NMDA receptors. Concentration-response relationships were determined for these agonists at each NR2 subunit. We find consistently higher potency at the NR2D subunit for a wide range of dissimilar structures, with (2S,4R)-4-methylglutamate (SYM2081) showing the greatest differential potency between NR2A- and NR2D-containing receptors (46-fold). Analysis of chimeric NR2A/D receptors suggests that enhanced agonist potency for NR2D is controlled by residues in both of the domains (Domain1 and Domain2) that compose the bilobed agonist binding domain. Molecular dynamics (MD) simulations comparing a crystallography-based hydrated NR1/NR2A model with a homology-based NR1/NR2D hydrated model of the agonist binding domains suggest that glutamate exhibits a different binding mode in NR2D compared with NR2A that accommodates a 4-methyl substitution in SYM2081. Mutagenesis of functionally divergent residues supports the conclusions drawn based on the modeling studies. Despite high homology and conserved atomic contact residues within the agonist binding pocket of NR2A and NR2D, glutamate adopts a different binding orientation that could be exploited for the development of subunit selective agonists and competitive antagonists.


Received April 22, 2007; accepted July 10, 2007

Address correspondence to: Dr. Stephen F. Traynelis, Department of Pharmacology, Emory University School of Medicine, 5025 Rollins Research Center, 1510 Clifton Road, Atlanta GA 30322-3090. E-mail: strayne{at}emory.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. L. Blanke and A. M. J. VanDongen
Constitutive Activation of the N-Methyl-D-aspartate Receptor via Cleft-spanning Disulfide Bonds
J. Biol. Chem., August 1, 2008; 283(31): 21519 - 21529.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
D. C. Wrighton, E. J. Baker, P. E. Chen, and D. J. A. Wyllie
Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes
J. Physiol., January 1, 2008; 586(1): 211 - 225.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
P. E. Chen, M. T. Geballe, E. Katz, K. Erreger, M. R. Livesey, K. K. O'Toole, P. Le, C. J. Lee, J. P. Snyder, S. F. Traynelis, et al.
Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes
J. Physiol., January 1, 2008; 586(1): 227 - 245.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics